Stock Analiz

Ultragenyx Pharmaceutical Inc. (RARE) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Ultragenyx Pharmaceutical’s revenue went from $133000 in fiscal 2016 to $673M in fiscal 2025, growth of about 158.0% a year.

Net income in fiscal 2025 was -$575M, a net margin of -85.4%; the best year in this period was 2020 with -$187M.

Over the twelve months to September 30, 2026, revenue was $730M and net income -$524M.

Free cash flow was -$472M in fiscal 2025 and positive in 0 of the 10 years shown.

The diluted share count rose 149% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $133000162017: $3M172018: $51M182019: $104M192020: $271M202021: $351M212022: $363M222023: $434M232024: $560M242025: $673M25$673M
Net income
2016: -$246M162017: -$302M172018: -$198M182019: -$403M192020: -$187M202021: -$454M212022: -$707M222023: -$607M232024: -$569M242025: -$575M25-$575M
Free cash flow
2016: -$171M162017: -$257M172018: -$295M182019: -$370M192020: -$176M202021: -$412M212022: -$497M222023: -$519M232024: -$421M242025: -$472M25-$472M
EPS (diluted)
2016: $-6.21162017: $-7.12172018: $-3.97182019: $-7.12192020: $-3.07202021: $-6.70212022: $-10.12222023: $-8.25232024: $-6.29242025: $-5.8325$-5.83

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$730M$673M$560M$434M$363M$351M$271M$104M$51M$3M$133000
Gross profit————————$50M$3M—
Operating income-$467M-$535M-$536M-$569M-$649M-$382M-$330M-$424M-$371M-$329M-$248M
Net income-$524M-$575M-$569M-$607M-$707M-$454M-$187M-$403M-$198M-$302M-$246M
EPS (diluted)$-5.18$-5.83$-6.29$-8.25$-10.12$-6.70$-3.07$-7.12$-3.97$-7.12$-6.21
R&D$711M$750M$698M$648M$706M$497M$412M$357M$294M$232M$183M
Revenue growth—+20.2%+29.0%+19.4%+3.4%+29.7%+161.3%+101.4%+1871.5%+1863.9%—

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow-$437M-$466M-$414M-$475M-$380M-$339M-$132M-$345M-$291M-$254M-$161M
Capital spending-$5M-$6M-$7M-$44M-$116M-$73M-$44M-$25M-$4M-$3M-$10M
Free cash flow-$442M-$472M-$421M-$519M-$497M-$412M-$176M-$370M-$295M-$257M-$171M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————————
Stock-based pay$105M$153M$158M$135M$130M$105M$86M$82M$80M$68M$48M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$680M$610M$578M$748M$740M$1.2B$755M$460M$234M$380M
Debt—$36M$40M$43M$31M$41M$47M$37M$0$0$0
Equity—-$80M$255M$275M$352M$923M$1.2B$654M$609M$383M$474M
Total assets—$1.5B$1.5B$1.5B$1.5B$1.5B$1.8B$1.1B$720M$491M$541M
Shares (diluted)102M99M90M74M70M68M61M57M50M42M40M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin————————97.8%100.0%—
Operating margin-64.0%-79.5%-95.7%-131.1%-178.6%-108.6%-121.8%-409.0%-721.2%-12593.5%-186500.0%
Net margin-71.8%-85.4%-101.6%-139.9%-194.7%-129.2%-68.8%-388.3%-383.8%-11567.3%-184900.0%
FCF margin-60.5%-70.1%-75.2%-119.6%-136.7%-117.2%-65.0%-357.0%-572.2%-9825.3%-128700.0%
ROIC——-143.4%-178.2%-133.7%-31.3%-21.7%-48.5%-48.2%-81.4%-41.3%
ROE—718.8%-223.1%-220.7%-201.0%-49.2%-16.2%-61.6%-32.5%-78.8%-51.9%

Frequently asked questions

What is Ultragenyx Pharmaceutical’s annual revenue?

$673M in fiscal 2025 and $730M over the twelve months to September 30, 2026.

How much profit does Ultragenyx Pharmaceutical make?

Net income was -$575M in fiscal 2025 (net margin -85.4%).

Is Ultragenyx Pharmaceutical’s revenue growing?

Yes: revenue rose 20.2% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.